GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (BUE:GSK) » Definitions » Cyclically Adjusted Price-to-FCF

GSK (BUE:GSK) Cyclically Adjusted Price-to-FCF : 13.18 (As of May. 19, 2024)


View and export this data going back to . Start your Free Trial

What is GSK Cyclically Adjusted Price-to-FCF?

As of today (2024-05-19), GSK's current share price is ARS12400.00. GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ARS940.82. GSK's Cyclically Adjusted Price-to-FCF for today is 13.18.

The historical rank and industry rank for GSK's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BUE:GSK' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 9.39   Med: 13.04   Max: 19.16
Current: 12.87

During the past years, GSK's highest Cyclically Adjusted Price-to-FCF was 19.16. The lowest was 9.39. And the median was 13.04.

BUE:GSK's Cyclically Adjusted Price-to-FCF is ranked better than
85.06% of 328 companies
in the Drug Manufacturers industry
Industry Median: 33.52 vs BUE:GSK: 12.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GSK's adjusted free cash flow per share data for the three months ended in Mar. 2024 was ARS51.405. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ARS940.82 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


GSK Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GSK's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Price-to-FCF Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.02 11.16 12.90 10.25 10.53

GSK Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.38 10.09 10.88 10.53 12.39

Competitive Comparison of GSK's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted Price-to-FCF falls into.



GSK Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GSK's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=12400.00/940.82
=13.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, GSK's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=51.405/131.6000*131.6000
=51.405

Current CPI (Mar. 2024) = 131.6000.

GSK Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.656 99.800 0.865
201409 1.499 100.000 1.973
201412 2.823 99.900 3.719
201503 0.008 99.600 0.011
201506 -0.359 100.100 -0.472
201509 0.070 100.200 0.092
201512 2.020 100.400 2.648
201603 -0.308 100.400 -0.404
201606 1.939 101.000 2.526
201609 3.179 101.500 4.122
201612 5.565 102.200 7.166
201703 1.761 102.700 2.257
201706 1.069 103.500 1.359
201709 4.146 104.300 5.231
201712 7.051 105.000 8.837
201803 1.807 105.100 2.263
201806 4.124 105.900 5.125
201809 9.953 106.600 12.287
201812 20.844 107.100 25.612
201903 2.321 107.000 2.855
201906 5.347 107.900 6.521
201909 17.763 108.400 21.565
201912 26.005 108.500 31.542
202003 5.951 108.600 7.211
202006 25.139 108.800 30.407
202009 2.540 109.200 3.061
202012 44.745 109.400 53.825
202103 -0.357 109.700 -0.428
202106 12.141 111.400 14.343
202109 22.579 112.400 26.436
202112 53.242 114.700 61.087
202203 34.305 116.500 38.751
202206 17.182 120.500 18.765
202209 16.187 122.300 17.418
202212 28.808 125.300 30.256
202303 -13.968 126.800 -14.497
202306 22.862 129.400 23.251
202309 90.318 130.100 91.359
202312 133.817 130.500 134.945
202403 51.405 131.600 51.405

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GSK  (BUE:GSK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GSK Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (BUE:GSK) Business Description

Industry
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.